UK MHRA amends medtech regulations to place vCJD assays in highest-risk category
This article was originally published in Clinica
Executive Summary
The UK government has amended its medtech rules to ensure that medical devices that are used to identify variant Creutzfeldt-Jakob Disease (vCJD) in human blood undergo the highest possible level of scrutiny before they are placed on the market.